What a year of semaglutide actually costs

Every price you see is monthly. Every course of treatment is annual. The gap between those two numbers is where the real cost hides.

Why the monthly number misleads

Semaglutide is a long-term therapy. Weight-management trials run 64 to 68 weeks, and discontinuation studies show substantial weight regain after stopping — so the honest planning horizon is a year or more, not a month. Yet every program advertises a monthly price, and often the lowest monthly price on offer: the starter dose, the first month, or the 12-month prepaid rate.

The result is a systematic understatement. A program advertising “from $99” may bill $99 only at the starting dose, only on a 12-month commitment, or only for the first shipment. The annual total — what you will actually pay across twelve months of real treatment — is the number that lets you compare programs honestly, and it is almost never the one on the landing page.

Brand semaglutide across a year

Injectable Wegovy at self-pay retail runs several hundred dollars a month; through NovoCare's cash-pay channel the figure is lower but still lands a year in the multiple-thousands. Across twelve months at maintenance, brand injectable Wegovy self-pay sits in the roughly $4,000–$6,000 range depending on channel and any savings offer, before clinic or lab fees.

The Wegovy pill changes the brand math. At $149 for starter doses and about $299 for the 9 and 25 mg maintenance doses, a titrated year lands roughly $2,900–$3,200 self-pay — the cheapest FDA-approved route to semaglutide for a cash-pay weight-loss patient without insurance. Insured copays, where a plan covers weight-loss GLP-1s, can drop any of these to a few hundred dollars for the year.

Compounded injectable across a year

Legitimate compounded injectable semaglutide programs, where lawfully available, cluster around $100–$200 per month all-inclusive, putting a year near $1,200–$2,400. That is the floor of the semaglutide market and the reason the compounded route grew — though, as our compounding-rules guide explains, the post-shortage legal constraints now limit who can lawfully provide it and on what basis.

The annual-cost caveat still applies: check whether that monthly rate requires a 12-month prepaid commitment, whether shipping and clinician fees are included, and whether the price holds at every dose. Flat-priced programs that don't charge more as you titrate produce a predictable annual total; dose-priced programs do not.

Sublingual ODT across a year

Compounded sublingual semaglutide ODT programs are priced separately and should be evaluated separately, because — as our ODT evidence guide details — there is no formulation-specific trial evidence that a sublingual tablet delivers the dose an injection does. A representative ODT program runs $199 per month monthly, dropping to $165–$177 on committed plans, so an annual total of roughly $1,980–$2,388.

That annual figure looks competitive with injectable options, but the comparison is not apples-to-apples: you are paying for a route whose dose-to-effect relationship is unestablished. A lower annual price for an unproven formulation is not automatically better value than a higher price for a proven one.

The fees that inflate the real total

Beyond the medication, annual totals swell from fees that monthly ads omit: mandatory membership charges, required lab work, clinician consultation fees, shipping, onboarding fees, and dose-increase surcharges. A $99 headline plus a $40 monthly membership plus $75 in labs plus $15 shipping is not a $99 program; it is a $170 program, and $2,040 across the year.

The discipline that protects you is the effective-monthly-cost calculation: total all mandatory payments for the treatment period, divide by months supplied. Do that for every program on the same basis — our affordability methodology sets it out — and the annual comparison becomes honest. Anything hidden in tooltips or disclosed only at checkout belongs in the total.

A worked 12-month comparison

Consider four routes for a cash-pay weight-loss patient, titrating normally. Compounded injectable at a flat $150/month all-in: about $1,800 for the year. Sublingual ODT at $165/month on a 12-month plan: $1,980, for an unproven route. The Wegovy pill titrated: roughly $3,000, FDA-approved. Brand injectable Wegovy self-pay: roughly $5,000, FDA-approved, highest evidence.

Ranked by annual cost, compounded injectable wins; ranked by evidence-per-dollar, the picture shifts toward the approved products. The right choice depends on which axis matters to you — and on legality and eligibility, which are individual. What the annual view does is stop the $99-versus-$149 monthly comparison from hiding a $3,000 annual gap.

Frequently asked questions

Why is the annual cost so different from the monthly price?

Advertised monthly prices are usually the lowest possible: starter dose, first month, or a 12-month prepaid rate. The annual total reflects titration to maintenance doses, mandatory fees, and the full commitment — which the monthly headline omits.

What's the cheapest legal annual route?

For an insured patient whose plan covers weight-loss semaglutide, copay pricing (~$300/year) is cheapest. Self-pay, the Wegovy pill is the cheapest FDA-approved route; compounded injectable is lower still where lawfully available, with the legality caveats covered on this site.

Should I prepay a 12-month plan to save?

Committed plans lower the monthly rate but bind you for a year and often restrict refunds on dispensed medication. Weigh the savings against the cancellation terms, especially for a therapy you may need to adjust or stop.

Sources

1. Wegovy pill launch pricing (Fierce Pharma)
2. Drug Topics — compounded vs brand cost context
3. NovoCare — Wegovy access
4. Our affordability methodology

Sources: FDA — human drug compounding and GLP-1 status; clinical evidence via NEJM. Pricing captured September 2026; see evidence ledger. Last reviewed September 2026.